| Active substance | GLP-1 RA |
|---|---|
| Reference | CRX038 |
| Side effects | Nausea, vomiting, diarrhea, abdominal pain, decreased appetite |
| Effects | Improved glycemic control, weight loss |
| Dosage (sports) | Not recommended for use in sports |
| Dosage (medical) | 0.25 mg once weekly, increasing to 0.5 mg and up to 1 mg as tolerated and needed |
| Half-life | Approximately 1 week |
| Main action | Lowers blood glucose levels |
| Substance class | GLP-1 receptor agonist |
| Formula | C187H291N45O59 |
| Chemical name | Semaglutide |
| Storage conditions | Store in a refrigerator at 2В°C to 8В°C (36В°F to 46В°F) |
| ean13 | 1377450676413 |
| Dosage Unit | Ml |
| Milliliter Size | 4 Ml |
| FORM | Injection |
| Trade name | Ozempic, Rybelsus |
| Blood pressure | Can cause a reduction in blood pressure |
| Also known as | N/A |
| Lab Test | Blood glucose levels, HbA1c |
| Hepatotoxicity | Low risk |
| Water Retention | Minimal |
| Dosage | 5 Mg |
| Use in sports | None, not indicated for performance enhancement |
| Packing | Vial |
Reviews
There are no reviews yet.